Ziping F. Wang

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 101 publications

Correction: Isolation, culture, and in vitro functional validation of intratumor bacteria from lung cancer patients.

Correction: Isolation, culture, and in vitro functional validation of intratumor bacteria from lung cancer patients.

Journal: BMC microbiology
Published: January 16, 2026

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 04, 2025

Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.

Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.

Journal: Future oncology (London, England)
Published: October 30, 2025

Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study.

Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study.

Journal: Translational lung cancer research
Published: June 17, 2025

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Journal: Lancet (London, England)
Published: June 11, 2025

Isolation, culture, and in vitro functional validation of intratumor bacteria from lung cancer patients.

Isolation, culture, and in vitro functional validation of intratumor bacteria from lung cancer patients.

Journal: BMC microbiology
Published: June 05, 2025

Pemetrexed plus platinum outperforms other platinum-based adjuvant chemotherapy regimens for resected stage II-IIIA lung adenocarcinoma: an open-label, historical-control study.

Pemetrexed plus platinum outperforms other platinum-based adjuvant chemotherapy regimens for resected stage II-IIIA lung adenocarcinoma: an open-label, historical-control study.

Journal: Journal of thoracic disease
Published: May 23, 2025

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).

Journal: Future oncology (London, England)
Published: December 04, 2024

Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.

Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 04, 2024

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.

Journal: The Lancet. Oncology
Published: November 11, 2024

Lactate production by tumor-resident Staphylococcus promotes metastatic colonization in lung adenocarcinoma.

Lactate production by tumor-resident Staphylococcus promotes metastatic colonization in lung adenocarcinoma.

Journal: Cell host & microbe
Published: November 10, 2024

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Journal: Signal transduction and targeted therapy
Published: August 25, 2024
Showing 1-12 of 101

Last Updated: 09/26/2026